Epizyme to Participate in Jefferies Virtual Healthcare Conference
Epizyme (Nasdaq: EPZM) announced that its President and CEO, Robert Bazemore, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 p.m. ET. A live webcast will be available on the Company’s investor website, with an archive accessible for 60 days post-event.
Epizyme is focused on developing innovative epigenetic therapies, including its FDA-approved product TAZVERIK (tazemetostat) for certain cancer indications.
- None.
- None.
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. ET.
A live webcast of the fireside chat will be available in the investor section of the Company's website at www.epizyme.com, and will be archived for 60 days following the call.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials(s). The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.
TAZVERIK® is a registered trademark of Epizyme, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005255/en/
FAQ
When is Epizyme's fireside chat at the Jefferies Virtual Healthcare Conference?
Who will participate in Epizyme's fireside chat?
Where can I watch the Epizyme fireside chat?
What is TAZVERIK and its approval status?
What is Epizyme's focus in biopharmaceuticals?
